Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. (Q34017621)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

9 November 2019

review article

1 reference

title

Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

9 November 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

9 November 2019

author name string

A Ezra

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

9 November 2019

language of work or name

English

0 references

publication date

1 August 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

Advanced Drug Delivery Reviews

9 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

9 November 2019

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

9 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

9 November 2019

page(s)

175-195

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

Bisphosphonates: preclinical aspects and use in osteoporosis

9 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonate therapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Use of bisphosphonates in cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The management of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Rationale for the use of bisphosphonates in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonate therapy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonate therapy

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Alendronate treatment for osteoporosis: a review of the clinical evidence.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonates and the treatment of bone disease in the elderly

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Comparative clinical pharmacology and therapeutic use of bisphosphonates in metabolic bone diseases

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The inhibition of calcium hydroxypatite crystal growth by polyphosphonates and polyphosphates

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The influence of multidentate organic phosphonates on the crystal growth of hydroxyapatite

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Aggregation of hydroxyapatite crystals

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonates act on rat bone resorption through the mediation of osteoblasts

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Structure-activity relationships of various bisphosphonates

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonates: a review of their pharmacokinetic properties

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Retention of etidronate in human, dog, and rat

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Distribution of [14C]clodronate (dichloromethylene bisphosphonate) disodium in mice

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The tissue distribution of clodronate (dichloromethylene bisphosphonate) in mice. The effects of vehicle and the route of administration

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Comparison of the distribution of three bisphosphonates in mice

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Metabolism of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) in the rat, rabbit, dog and monkey

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Clinical pharmacology of alendronate sodium

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Clodronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Intestinal absorption of disodium ethane-1-hydroxy-1,1-diphosphonate (disodium etidronate) using a deconvolution technique.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Pharmacokinetic evaluation of pamidronate after oral administration: a study on dose proportionality, absolute bioavailability, and effect of repeated administration

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Clodronate kinetics and bioavailability

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

On the absorption of alendronate in rats

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Absorption of oral diphosphonate in normal subjects

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Studies of the oral bioavailability of alendronate

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Esophagitis associated with the use of alendronate

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Intestinal drug absorption enhancement: an overview

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Dose-dependent absorption of disodium etidronate

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The gastrointestinal absorption of drugs in man: a review of current concepts and methods of investigation

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Cytotoxic effects of pamidronate on monolayers of human intestinal epithelial (Caco-2) cells and its epithelial transport

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Sodium EDTA enhances intestinal absorption of two bisphosphonates

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Oral tiludronate: pharmacological properties and potential usefulness in Paget's disease of bone and osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The therapeutic use of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Risedronate gastrointestinal absorption is independent of site and rate of administration

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

3-Amino-1-hydroxypropylidene-1,1-diphosphonate (APD): a novel enhancer of rectal cefoxitin absorption in rats

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Reduction in calcium excretion in women with breast cancer and bone metastases using the oral bisphosphonate pamidronate

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Paget's disease of bone: early and late responses to three different modes of treatment with aminohydroxypropylidene bisphosphonate (APD).

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Efficacy of amino-hydroxypropylidene bisphosphonate in hypercalcemia: observations on regulation of serum calcium

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Effect of dosage form and formulation factors on the adherence of drugs to the esophagus

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Esophageal irritation due to alendronate sodium tablets: possible mechanisms

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Adverse effects of bisphosphonates. A comparative review

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Nonclinical model for assessing gastric effects of bisphosphonates

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The effects of nitrogen-containing bisphosphonates on human epithelial (Caco-2) cells, an in vitro model for intestinal epithelium

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Synthesis and preclinical pharmacology of 2-(2-aminopyrimidinio) ethylidene-1,1-bisphosphonic acid betaine (ISA-13-1)-a novel bisphosphonate.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisacylphosphonates inhibit hydroxyapatite formation and dissolution in vitro and dystrophic calcification in vivo

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Biological and clinical assessment of a new bisphosphonate, (chloro-4 phenyl) thiomethylene bisphosphonate, in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Efficacy and tolerability of a new formulation of oral tiludronate (tablet) in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Evaluation of the efficacy and safety of oral tiludronate in Paget's disease of bone. A double-blind, multiple-dosage, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Pamidronate: An unrecognized problem in gastrointestinal tolerability

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Long-term effects of a treatment course with oral alendronate of postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Effects of oral alendronate and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Effects of two oral doses of alendronate in the treatment of Paget's disease of bone

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Dose-dependent effect of calcium and magnesium etidronate on salicylic acid absorption in the rat

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonate prodrugs: synthesis and in vitro evaluation of novel clodronic acid dianhydrides as bioreversible prodrugs of clodronate

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Concentration and pH dependency of alpha-methyldopa absorption in rat intestine

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

The effect of size and shape of tablets on their esophageal transit

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Mechanism of L-alpha-methyldopa transport through a monolayer of polarized human intestinal epithelial cells (Caco-2).

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Evidence of a specialized transport mechanism for the intestinal absorption of baclofen.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Sodium and pH dependent carrier-mediated transport of antibiotic, fosfomycin, in the rat intestinal brush-border membrane.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Na and pH dependent transport of foscarnet via the phosphate carrier system across intestinal brush-border membrane

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Intestinal absorption mechanism of amphoteric β-lactam antibiotics II: Michaelis—menten kinetics of cyclacillin absorption and its pharmacokinetic analysis in rats

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Interaction of renin inhibitors with the intestinal uptake system for oligopeptides and beta-lactam antibiotics

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Passive and carrier-mediated intestinal absorption components of two angiotensin converting enzyme (ACE) inhibitor prodrugs in rats: enalapril and fosinopril

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Use of the peptide carrier system to improve the intestinal absorption of L-alpha-methyldopa: carrier kinetics, intestinal permeabilities, and in vitro hydrolysis of dipeptidyl derivatives of L-alpha-methyldopa

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Valacyclovir: a substrate for the intestinal and renal peptide transporters PEPT1 and PEPT2.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Anticalcification and antiresorption effects of bisacylphosphonates

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonates and tetracycline: experimental models for their evaluation in calcium-related disorders

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Intranasal delivery of the bisphosphonate alendronate in the rat and dog

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Nasal delivery. The use of animal models to predict performance in man.

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Pharmacokinetics of Clodronate after Single Intravenous, Intramuscular and Subcutaneous Injections in Rats

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Intramuscular clodronate therapy in postmenopausal osteoporosis

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Subcutaneous clodronate: A study evaluating efficacy in hypercalcemia of malignancy and local toxicity

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Preparation and Evaluation of Chitosan Microspheres Containing Bisphosphonates

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Arthroplasty implant biomaterial particle associated macrophages differentiate into lacunar bone resorbing cells

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: synthesis and in vivo characterization of osteotropic carboxyfluorescein

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: Pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I.v. effects of osteotropic estradiol on bone mineral density and uterine weight in ovariectomized rats

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

Structural specificity of mucosal-cell transport and metabolism of peptide drugs: implication for oral peptide drug delivery

1 reference

https://api.crossref.org/works/10.1016/S0169-409X(00)50061-2

7 January 2021

10.1016/S0169-409X(00)00061-2

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10963835 AND SRC:MED&resulttype=core&format=json

9 November 2019

1 reference